According to GlobalData’s company profile on Genentech USA, was a key innovation area identified from patents.

Treatment method for fibrotic, inflammatory, or autoimmune disorders using compound i

The granted patent (Publication Number: US11925624B2) discloses a method for providing Compound I therapy to a subject in need. The method involves evaluating the subject's renal function, specifically by determining the creatinine clearance rate. Different creatinine clearance ranges are specified, from =90 mL/min to 15-29 mL/min, indicating varying levels of renal function. Importantly, the method excludes subjects with end-stage renal disease requiring dialysis, ensuring the therapy's suitability for specific renal conditions.

Additionally, the method includes monitoring changes in the subject's serum creatinine level post-therapy administration. Based on these changes, adjustments to the Compound I dosage or discontinuation of therapy may be recommended. Notably, specific criteria are outlined for advising the subject to discontinue Compound I therapy, such as a significant increase in serum creatinine levels. Furthermore, the patent specifies that the subject targeted for this therapy is suffering from a fibrotic disorder, with a particular mention of idiopathic pulmonary fibrosis (IPF). This targeted approach highlights the potential efficacy of Compound I therapy in managing fibrotic conditions, particularly IPF, showcasing a specialized treatment method for these specific medical conditions.

To know more about GlobalData’s detailed insights on Genentech USA, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed